Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Composition : Empagliflozin (5mg) + Metformin (850mg) Tablet
Dosage Form : Tablet
Packaging Type : Alu Alu
Packaging : 10*10
Price : ₹0/-
Emplozin M 5/850 Tablet is a scientifically formulated dual-drug oral therapy combining Empagliflozin 5mg and Metformin 850mg, designed to provide effective blood sugar control in patients with type-2 diabetes mellitus.
Empagliflozin helps lower blood glucose by promoting renal glucose excretion, while Metformin improves insulin sensitivity and reduces hepatic glucose production. Together, they provide balanced management of fasting and postprandial blood sugar levels.
This combination is widely prescribed for patients requiring dual therapy with improved metabolic control, offering efficacy along with a favorable safety profile. Its once-daily dosing supports patient adherence in chronic diabetes management.
Adding Emplozin M 5/850 Tablet to your diabetes and metabolic-care portfolio strengthens your market offerings, creating strong opportunities in retail pharmacy supply, hospital procurement, institutional distribution, export channels, and third-party manufacturing. Its high prescription demand ensures consistent commercial performance.
Some patients may experience nausea, diarrhea, abdominal discomfort, increased urination, dizziness, or headache. Rarely, hypoglycemia (especially when used with other antidiabetic agents), urinary tract infections, genital infections, or lactic acidosis may occur.
Emplozin M 5/850 Tablet is indicated for the management of type 2 diabetes mellitus in patients who require dual therapy to achieve effective glycemic control when diet and exercise alone are insufficient.
Use strictly under medical supervision. Regular monitoring of blood glucose and kidney function is recommended. Avoid use in patients with severe renal impairment or metabolic acidosis. Follow the prescribed dosage and lifestyle guidance carefully.
Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.
Composition : Calcium Dobesilate Monohydrate I.P. 500 mg Capsule
Composition : L-Arginine (3gm) + Proanthocyanidin (75mg) sachet
Composition : Aminacrine HCl 0.1g + Cetrimide Cream 0.5g
Composition : Chlorhexidine Gluconate (0.20% w/w) + Silver Nitrate (0.20% w/w) cream
Composition : Hydroquinone (2% w/w) + Mometasone (0.1% w/w) + Tretinoin (0.025% w/w)
Composition : Fusidic Acid I.P. 2.00% w/w + Beclomethasone Dipropionate I.P. 0.025% w/w
Composition : Cranberry Extract 300mg + D-Mannose 600mg Tablet
Composition : Ketoconazole (2.0% w/w) + Clobetasol Propionate (0.05% w/w) + Neomycin (0.10% w/w) + Tolnaflate (1.0% w/w) + Iodochlorhydroxy Quinoline (1.0% w/w) Cream
Composition : Terbinafine (1% w/w)
Composition : Tretinoin 0.05% Cream
Strategic Advisory
Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.
View Professional Profile
Start Your Journey
Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our Successful network today.
Quick Navigation
1500+ Products
Our Divisions
All Therapeutics
Disclaimer: Pharma Insights are based on operational standards as of March 2026. All territories are subject to availability and Revised Schedule M compliance.